Oncolytic vaccines increase the response to PD-L1 blockade in immunogenic and poorly immunogenic tumors

References

• Loskog A, Ninalga C, Totterman TH. Dendritic cells engineered to express CD40 L continuously produce IL12 and resist negative signals from Tr1/Th3 dominated tumors. Cancer Immunol, Immunother: CII. 2006;55(5):588–97. doi:10.1007/s00262-005-0051-4.
   PubMed Web of Science ®Google Scholar
• Youn JI, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol. 2008;181(8):5791–802. doi:10.4049/jimmunol.181.8.5791. PMID:18832739.
   PubMed Web of Science ®Google Scholar
• Kodumudi KN, Woan K, Gilvary DL, Sahakian E, Wei S, Djeu JY. A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res. 2010;16(18):4583–94. doi:10.1158/1078-0432.CCR-10-0733. PMID:20702612.
   PubMed Web of Science ®Google Scholar
• Chaudhary B, Elkord E, Regulatory T. Cells in the tumor microenvironment and cancer progression: role and therapeutic targeting. Vaccines (Basel). 2016;4(3):28. PMID:27509527
   PubMed Web of Science ®Google Scholar
• Smahel M. PD-1/PD-L1 blockade therapy for tumors with Downregulated MHC Class I expression. Int J Mol Sci. 2017;18(6):1331. doi:10.3390/ijms18061331. PMID:28635644
   PubMed Web of Science ®Google Scholar
• Zhang L, Gajewski TF, Kline J. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood. 2009;114(8):1545–52. doi:10.1182/blood-2009-03-206672. PMID:19417208.
   PubMed Web of Science ®Google Scholar
• Reiser J, Banerjee A. Effector, memory, and dysfunctional CD8(+) T cell fates in the antitumor immune response. J Immunol Res. 2016;2016:8941260. doi:10.1155/2016/8941260. PMID:27314056.
   PubMedGoogle Scholar
• Fuertes Marraco SA, Neubert NJ, Verdeil G, Speiser DE. Inhibitory receptors beyond T cell exhaustion. Front Immunol. 2015;6:310. doi:10.3389/fimmu.2015.00310. PMID:26167163.
   PubMed Web of Science ®Google Scholar
• Callahan MK, Wolchok JD. At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol. 2013;94(1):41–53. doi:10.1189/jlb.1212631. PMID:23667165.
   PubMed Web of Science ®Google Scholar
• Liu J, Zhang S, Hu Y, Yang Z, Li J, Liu X, Deng L, Wang Y, Zhang X, Jiang T, et al. Targeting PD-1 and Tim-3 pathways to reverse CD8 T-cell exhaustion and enhance Ex Vivo T-cell responses to autologous dendritic/tumor vaccines. J Immunother. 2016;39(4):171–80. doi:10.1097/CJI.0000000000000122. PMID:27070448.
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Kroemer G. Targeting PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology. 2012;1(8):1223–5. doi:10.4161/onci.21335. PMID:23243584.
   PubMed Web of Science ®Google Scholar
• O'Donnell JS, Long GV, Scolyer RA, Teng MW, Smyth MJ. Resistance to PD1/PDL1 checkpoint inhibition. Cancer Treat Rev. 2017;52:71–81. doi:10.1016/j.ctrv.2016.11.007. PMID:27951441.
   PubMed Web of Science ®Google Scholar
• Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(4):707–23. doi:10.1016/j.cell.2017.01.017. PMID:28187290.
   PubMed Web of Science ®Google Scholar
• Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015;161(2):205–14. doi:10.1016/j.cell.2015.03.030. PMID:25860605.
   PubMed Web of Science ®Google Scholar
• Alemany R, Cascallo M. Oncolytic viruses from the perspective of the immune system. Future Microbiol. 2009;4(5):527–36. doi:10.2217/fmb.09.28. PMID:19492964.
   PubMed Web of Science ®Google Scholar
• Aurelian L. Oncolytic viruses as immunotherapy: progress and remaining challenges. Onco Targets Ther. 2016;9:2627–37. doi:10.2147/OTT.S63049. PMID:27226725.
   PubMed Web of Science ®Google Scholar
• Swart M, Verbrugge I, Beltman JB. Combination approaches with immune-checkpoint blockade in cancer therapy. Front Oncol. 2016;6:233. doi:10.3389/fonc.2016.00233. PMID:27847783.
   PubMed Web of Science ®Google Scholar
• Capasso C, Hirvinen M, Garofalo M, Romaniuk D, Kuryk L, Sarvela T, Vitale A, Antopolsky M, Magarkar A, Viitala T, et al. Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma. Oncoimmunology. 2016;5(4):e1105429. doi:10.1080/2162402X.2015.1105429. PMID:27141389.
   PubMed Web of Science ®Google Scholar
• Ali K, Soond DR, Pineiro R, Hagemann T, Pearce W, Lim EL, Bouabe H, Scudamore CL, Hancox T, Maecker H, et al. Inactivation of PI(3)K p110delta breaks regulatory T-cell-mediated immune tolerance to cancer. Nature. 2014;510(7505):407–11. doi:10.1038/nature13444. PMID:24919154.
   PubMed Web of Science ®Google Scholar
• Bunt SK, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J Immunol. 2006;176(1):284–90. doi:10.4049/jimmunol.176.1.284. PMID:16365420.
   PubMed Web of Science ®Google Scholar
• Cabezon T, Gromova I, Gromov P, Serizawa R, Timmermans Wielenga V, Kroman N, Celis JE, Moreira JM. Proteomic profiling of triple-negative breast carcinomas in combination with a three-tier orthogonal technology approach identifies Mage-A4 as potential therapeutic target in estrogen receptor negative breast cancer. Mol Cell Proteomics. 2013;12(2):381–94. doi:10.1074/mcp.M112.019786. PMID:23172894.
   PubMed Web of Science ®Google Scholar
• Mathe A, Wong-Brown M, Morten B, Forbes JF, Braye SG, Avery-Kiejda KA, Scott RJ. Novel genes associated with lymph node metastasis in triple negative breast cancer. Sci Rep. 2015;5:15832. doi:10.1038/srep15832. PMID:26537449.
   PubMed Web of Science ®Google Scholar
• Stagg J, Allard B. Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects. Ther Adv Med Oncol. 2013;5(3):169–81. doi:10.1177/1758834012475152. PMID:23634195.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–64. doi:10.1038/nrc3239. PMID:22437870.
   PubMed Web of Science ®Google Scholar
• Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56–61. doi:10.1126/science.aaa8172. PMID:25838373.
   PubMed Web of Science ®Google Scholar
• Kohlhapp FJ, Kaufman HL, Molecular pathways: mechanism of action for Talimogene Laherparepvec, a new oncolytic virus immunotherapy. Clin Cancer Res. 2016;22(5):1048–54. doi:10.1158/1078-0432.CCR-15-2667. PMID:26719429
   PubMed Web of Science ®Google Scholar
• Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS, et al. Talimogene Laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780–8. doi:10.1200/JCO.2014.58.3377. PMID:26014293.
   PubMed Web of Science ®Google Scholar
• Rehman H, Silk AW, Kane MP, Kaufman HL. Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy. J Immunother Cancer. 2016;4:53. doi:10.1186/s40425-016-0158-5. PMID:27660707.
   PubMed Web of Science ®Google Scholar
• Haanen J. Converting cold into hot tumors by combining immunotherapies. Cell. 2017;170(6):1055–6. doi:10.1016/j.cell.2017.08.031. PMID:28886376.
   PubMed Web of Science ®Google Scholar
• Galon J, Fox BA, Bifulco CB, Masucci G, Rau T, Botti G, Marincola FM, Ciliberto G, Pages F, Ascierto PA, et al. Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015. J Transl Med. 2016;14:273. doi:10.1186/s12967-016-1029-z. PMID:27650038.
   PubMed Web of Science ®Google Scholar
• Woller N, Gurlevik E, Fleischmann-Mundt B, Schumacher A, Knocke S, Kloos AM, Saborowski M, Geffers R, Manns MP, Wirth TC, et al. Viral infection of tumors overcomes resistance to PD-1-Immunotherapy by Broadening Neoantigenome-directed T-cell responses. Mol Ther. 2015;23(10):1630–40. doi:10.1038/mt.2015.115. PMID:26112079.
   PubMed Web of Science ®Google Scholar
• Cho HI, Celis E. Design of immunogenic and effective multi-epitope DNA vaccines for melanoma. Cancer Immunol Immunother: CII. 2012;61(3):343–51. doi:10.1007/s00262-011-1110-7.
   PubMed Web of Science ®Google Scholar
• Galaine J, Borg C, Godet Y, Adotevi O, Interest of Tumor-specific CD4 T Helper 1 cells for therapeutic anticancer vaccine. Vaccines (Basel). 2015;3(3):490–502. doi:10.3390/vaccines3030490. PMID:26350591.
   PubMed Web of Science ®Google Scholar
• Aarntzen EH, De Vries IJ, Lesterhuis WJ, Schuurhuis D, Jacobs JF, Bol K, Schreibelt G, Mus R, De Wilt JH, Haanen JB, et al. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. Cancer Res. 2013;73(1):19–29. doi:10.1158/0008-5472.CAN-12-1127. PMID:23087058.
   PubMed Web of Science ®Google Scholar
• Melief CJ, van der Burg SH. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer. 2008;8(5):351–60. doi:10.1038/nrc2373. PMID:18418403.
   PubMed Web of Science ®Google Scholar
• Mantovani A. The yin-yang of tumor-associated neutrophils. Cancer Cell. 2009;16(3):173–4. doi:10.1016/j.ccr.2009.08.014. PMID:19732714.
   PubMed Web of Science ®Google Scholar
• Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, Worthen GS, Albelda SM. Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN. Cancer Cell. 2009;16(3):183–94. doi:10.1016/j.ccr.2009.06.017. PMID:19732719.
   PubMed Web of Science ®Google Scholar
• Van Voorhis WC, Coculture of human peripheral blood mononuclear cells with Trypanosoma cruzi leads to proliferation of lymphocytes and cytokine production. J Immunol. 1992;148(1):239–48. PMID:1727869.
   PubMed Web of Science ®Google Scholar